Drug safety evaluation of certolizumab pegol

Bibliography

• Sandborn WJ. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology 2008;135(5):1442-7
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatolo 2006;33(12):2398-408
   PubMed Web of Science ®Google Scholar
• Colombel JF, Feagan BG, Sandborn WJ, et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012;18(2):349-58
   PubMed Web of Science ®Google Scholar
• van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013;9(3):164-72
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132(1):52-65
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362(15):1383-95
   PubMed Web of Science ®Google Scholar
• Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008;135(5):1493-9
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359(9317):1541-9
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130(2):323-33
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004;99(1):91-6
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340(18):1398-405
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117(4):761-9
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: data From the EXTEND Trial. Gastroenterology 2012;142(5):1102-11
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56(9):1232-9
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350(9):876-85
   PubMed Web of Science ®Google Scholar
• Perrier C, Rutgeerts P. New drug therapies on the horizon for IBD. Dig Dis 2012;30:100-5
   PubMed Web of Science ®Google Scholar
• Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68(6):789-96
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis twenty-four-week results of a phase iii, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheumatism 2009;60(8):2272-83
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial. Arthritis Rheum 2003;48(1):35-45
   PubMed Web of Science ®Google Scholar
• van de Putte BA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63(5):508-16
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy - A randomized, placebo-controlled, 52-week trial. Arthritis Rheumatism 2004;50(5):1400-11
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor : fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340(4):253-9
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis - A randomized, controlled trial. Ann Intern Med 1999;130(6):478-86
   PubMed Web of Science ®Google Scholar
• Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67(8):1096-103
   PubMed Web of Science ®Google Scholar
• Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354(9194):1932-9
   PubMed Web of Science ®Google Scholar
• Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology 2012;51:28-36
   Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007;13(11):1323-32
   PubMed Web of Science ®Google Scholar
• Choy E, McKenna F, Vencovsky J, et al. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Rheumatology (Oxford) 2012;51(7):1226-34
   PubMed Web of Science ®Google Scholar
• Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68(6):797-804
   PubMed Web of Science ®Google Scholar
• Keystone E, van der Heijde D, Mason D, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis findings of a fifty-two-week, phase iii, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58(11):3319-29
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Annu Rheum 2009;68(6):805-11
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357(3):228-38
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Abreu MT, D'Haens G, et al. Certolizumab pegol in patients with moderate to severe crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010;8(8):688-95
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol for active crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 2011;9(8):670-84
   PubMed Web of Science ®Google Scholar
• Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129(3):807-18
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357(3):239-50
   PubMed Web of Science ®Google Scholar
• Chapman AP, Antoniw P, Spitali M, et al. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 1999;17(8):780-3
   PubMed Web of Science ®Google Scholar
• Baker T, Kevorkian L, Nesbitt A. Investigation into the binding affinity of certolizumab pegol to FcRn and functional consequences for FcRn-mediated transcytosis: comparison to infliximab, adalimumab and etanercept. Ann Rheum Dis 2013;72(Suppl3):426
   Google Scholar
• Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs 2008;22(5):315-29
   PubMed Web of Science ®Google Scholar
• Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 2002;54(4):531-45
   PubMed Web of Science ®Google Scholar
• Eddleston A, Marenzama M, Marshall D, et al. Comparison of the distribution of an IgG and a pegylated Fab' form of an anti-TNFa antibody in the inflamed gut of colitic mice. Gut 2009;58:A305
   Google Scholar
• Palframan R, Airey M, Moore A, et al. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 2009;348(1-2):36-41
   PubMed Web of Science ®Google Scholar
• Bourne T, Fossati G, Nesbitt A. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. BioDrugs 2008;22(5):331-7
   PubMed Web of Science ®Google Scholar
• Lamour S, Bracher M, Nesbitt A. Effect of PEG component of certolizumab pegol on stimulated mast cell degranulation. Gut 2009;58:A305
   Google Scholar
• Derer S, Till A, Haesler R, et al. mTNF reverse signalling induced by TNFalpha antagonists involves a GDF-1 dependent pathway: implications for Crohn's disease. Gut 2012
   PubMed Web of Science ®Google Scholar
• Lichtenstein G, Thomsen O, Schreiber S, et al. Long-term remission with certolizumab pegol in crohn's disease: efficacy over 4.5 years in patients with no prior TNF inhibitor exposure (PRECiSE 3 Study). Am J Gastroenterol 2010;105:S417-18
   Web of Science ®Google Scholar
• Sandborn WJ, Schreiber S, Hanauer SB, et al. Reinduction with certolizumab pegol in patients with relapsed crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol 2010;8(8):696-702
   PubMed Web of Science ®Google Scholar
• Hebuterne X, Lemann M, Bouhnik Y, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013;62(2):201-8
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Schoepfer AM, Bansky G, et al. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflamm Bowel Dis 2011;17(7):1530-9
   PubMed Web of Science ®Google Scholar
• Hussain SZ, Feagan BG, Samad A, et al. Use of certolizumab pegol in children and adolescents with active Crohn's disease: pharmacokinetics over 6 weeks in the NURTURE study. Gastroenterology 2013;140(5):S265
   Web of Science ®Google Scholar
• Smolen J, van Vollenhoven R, Kavanaugh A, et al. Efficacy and safety of certolizumab pegol plus methotrexate in patients with rheumatoid arthritis: 3-year data from the rapid 2 study. Rheumatology 2011;50:123
   Web of Science ®Google Scholar
• Fleischmann RM, van Vollenhoven RF, Vencovsky J, et al. Long-term safety and efficacy of 4-weekly certolizumab pegol combination and monotherapy in rheumatoid arthritis: 5 year results from an open label extension study. Arthritis Rheum 2012;64(10):S565-6
   Web of Science ®Google Scholar
• Weinblatt ME, Fleischmann R, Huizinga TWJ, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology 2012;51(12):2204-14
   PubMed Web of Science ®Google Scholar
• Smolen JS, Emery P, Ferraccioli GF, et al. Efficacy and safety of certolizumab pegol after incomplete response to dmards in rheumatoid arthritis patients with low moderate disease activity: results from certain, a phase IIIb study. Rheumatology 2011;70(Suppl 3):259
   Google Scholar
• Yamamoto K, Takeuchi T, Yamanaka H, et al. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis. Arthritis Rheum 2011;63(Suppl 10):S476
   Web of Science ®Google Scholar
• Yamamoto K, Takeuchi T, Yamanaka H, et al. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate. Arthritis Rheum 2011;63(Suppl 10):S474-5
   Web of Science ®Google Scholar
• Furst DE, Shaikh SA, Greenwald M, et al. Evaluation of two dosing regimens of certolizumab pegol for maintenance of clinical response in patients with active rheumatoid arthritis: primary results from Doseflex, a phase IIIB study. Ann Rheum Dis 2012;71(Suppl 3):513
   Google Scholar
• Certolizumab pegol: Annex I: Summary of Product Characteristics. EMA Product information. 2013.
   Google Scholar
• van Vollenhoven R, Smolen J, Schiff M, et al. Safety update on certolizumab pegol (CZP) in patients with active rheumatoid arthritis (Ra). Rheumatology 2010;49:I102-3
   Web of Science ®Google Scholar
• Vencovsky J, Lortholary O, Gomez-Reino JJ, et al. The positive effect of stringent criteria for purified protein derivation (PPD) skin test on patients treated with certolizumab pegol. Ann Rheum Dis 2013;72(Suppl 3):233
   Google Scholar
• Mariette X, van Vollenhoven R, Bykerk VP, et al. Safety update on certolizumab pegol in patients with active rheumatoid arthritis with long term exposure. Arthritis Rheum 2012;64(10):S221
   Web of Science ®Google Scholar
• Kivitz A, Schechtman J, Texter M, et al. Assessment of immune responses to pneumococcal and influenza vaccines in patients with rheumatoid arthritis receiving certolizumab pegol. Arthritis Rheum 2011;63(10):S488
   PubMed Web of Science ®Google Scholar
• Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011(2):CD008794
   PubMed Web of Science ®Google Scholar
• Haraoui B, Combe B, Champsaur M, et al. Effects of different steroid doses on adverse events and radiographic progression of certolizumab pegol-treated rheumatoid arthritis patients. Ann Rheum Dis 2012;71(Suppl 3):498
   PubMedGoogle Scholar
• Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy - Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54(8):2368-76
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with crohn's disease: more than 5 years of follow-up in the TREAT (TM) Registry. Am J Gastroenterol 2012;107(9):1409-22
   PubMed Web of Science ®Google Scholar
• Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134(4):929-36
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374(9701):1617-25
   PubMed Web of Science ®Google Scholar
• Van Assche G, Lewis JD, Lichtenstein GR, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and Colitis organisation: safety. Am J Gastroenterol 2011;106(9):1594-602
   PubMed Web of Science ®Google Scholar
• Scherl E, Pierre-Louis B, Lee S. Formation of autoantibodies in patients with moderate to severe crohn's disease, receiving continuous and interrupted certolizumab pegol (CZP) therapy with or without concomitant immunosuppressants. Am J Gastroenterol 2011;106:S440
   Web of Science ®Google Scholar
• Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:286-92
   PubMed Web of Science ®Google Scholar
• Wakefield I, Stephens S, Foulkes R, et al. The use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNFalpha PEGylated Fab' monoclonal antibody. Toxicol Sci 2011;122(1):170-6
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Wolf D, Stach C, et al. Outcomes of pregnancy in subjects exposed to certolizumab pegol. Am J Gastroenterol 2012;107(Suppl 1):S621
   Google Scholar